Low-level viremia associated with the use of TaqMan assay.
Poor correlation has been reported between the Roche Cobas AmpliPrep/Cobas (TaqMan) HIV-1 TaqMan assay and the Roche Cobas Amplicor HIV-1 Monitor version 1.5 Amplicor assay. We report 8 patients who experienced unexplained detectable viremia, despite exemplary medication adherence, following a change in viral quantification assay from Amplicor to TaqMan in January 2008. All patients were found to have undetectable HIV RNA by branched DNA (bDNA) assay.
HIV Community Program, Christiana Care Health System, Wilmington, DE 19899, USA. sszabo@christianacare.org
Susan
S
Szabo
Lee E
LE
Moffett
Kelly
K
Cantwell-McNelis
Christopher W
CW
James
Abraham
A
Joseph
D000328:Adult; D044966:Anti-Retroviral Agents / Q000494:pharmacology / Q000627:therapeutic use; D021121:Branched DNA Signal Amplification Assay; D005260:Female; D015658:HIV Infections / Q000188:drug therapy / Q000821:virology*; D015497:HIV-1 / Q000187:drug effects / Q000302:isolation & purification* / Q000502:physiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D016133:Polymerase Chain Reaction / Q000379:methods*; D012367:RNA, Viral / Q000097:blood; D011933:Reagent Kits, Diagnostic; D012680:Sensitivity and Specificity; D019914:Taq Polymerase; D019562:Viral Load / Q000502:physiology*; D014766:Viremia / Q000188:drug therapy / Q000821:virology*
D044966:Anti-Retroviral Agents; D012367:RNA, Viral; D011933:Reagent Kits, Diagnostic; D019914:Taq Polymerase